ABSTRACT
Epidermal growth factor receptor (EGFR), a member of the super family of protein tyrosine kinase receptors, plays a crucial role in proliferation, apoptosis, aggression and metastasis of tumor cells. The target-EGFR inhibitors have been a hotspot and tendency in the progress of anti-tumors. Currently, the target-EGFR inhibitors have made a steady progress and many valuable drugs in the clinical treatment have been developed. However, many patients will be resistance to the drugs due to the mutation of amino acid. Therefore, drugs which can be effective in the later treatment or long-term therapies will always be deficient. In this article, the research progress and mechanism of anti-tumor of small molecules EGFR inhibitors in detail are reviewed.